EMEA-001679-PIP01-14
Key facts
| Active substance |
|
| Therapeutic area |
Infectious diseases
|
| Decision number |
P/0107/2015
|
| PIP number |
EMEA-001679-PIP01-14
|
| Pharmaceutical form(s) |
|
| Condition(s) / indication(s) |
Treatment of human immunodeficiency virus (HIV-1) infection
|
| Route(s) of administration |
Oral use
|
| Contact for public enquiries |
Gilead Sciences International Ltd
|
| Decision type |
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
|